Working Life: GlaxoSmithKline’s Thomas Webb
April 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Hong Kong, Working Life, macau, oncology, thomas webb
Thomas Webb, launch lead for GSK oncology Hong Kong and Macau How did you find your way into your current role? …
Novartis accused of Lucentis ‘campaign’ against Avastin
April 2, 2015Sales and Marketing Lucentis, NHS, Novartis, avastin, bevacizumab, ranibizumab, wet AMD
Novartis “embarked on a campaign to undermine and divert attention” from a cheap drug for vision loss and maintain the …
PM Society appoints two new members
April 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing colin williams, jonathan dancer, pm society
Not-for-profit healthcare marketing organisation PM Society has made two new appointments to its executive committee. Jonathan Dancer (pictured) the managing …
Takeda offers $2.2 billion to resolve Actos damages claims
April 1, 2015Sales and Marketing Actos, Cancer, Takeda, bladder, diabetes, heart, pioglitazone
Takeda has attempted to settle its hefty damages bill over claims it was hiding cancer risks in its diabetes drug …
Merck lines up early-stage Keytruda combo trial
April 1, 2015Research and Development, Sales and Marketing Cancer, Merck, entinostat, keytruda, pd1, pembrolizumab, syndax
Merck is planning for Keytruda’s future by launching early-stage trials of the drug in combination with an investigational treatment from …
Pfizer appoints inflammation and immunology head
April 1, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Charles Reay Mackay, Pfizer
Professor Charles Reay Mackay is joining US pharma giant Pfizer as the chief scientific officer of its inflammation and immunology …
Teva bolsters neurology unit through Auspex deal
March 31, 2015Sales and Marketing CNS, SD-809, Teva, Tourette syndrome, auspex, deutetrabenazine, neurology
Teva is significantly enhancing its neurology business by acquiring US biopharma firm Auspex in a deal worth $3.5 billion. Teva …
Novartis drug to treat iron overload gets US nod
March 31, 2015Sales and Marketing FDA, Novartis, blood, deferasirox, exjade, iron, jadenu
Novartis’ iron overload drug Jadenu has been given the green light by US regulators to treat patients with a serious …
Pfizer is pharma’s biggest advertiser
March 31, 2015Medical Communications, Sales and Marketing AbbVie, AstraZeneca, Pfizer, advertising, adverts, dtc, lilly
US giant Pfizer spends far more on direct-to-consumer advertising than any other pharma firm according to new data from Kantar …
Merck Serono in $826m immuno-oncology deal
March 31, 2015Research and Development, Sales and Marketing Intrexon, Merck, Merck Serono, T cell, biopharma, cart, immuno-oncology, t-cell
Merck Serono has announced a significant deal with Intrexon to develop and bring new cancer treatments to market. The German …
Roche subsidiary Genentech expands in manufacturing
March 31, 2015Manufacturing and Production, Sales and Marketing Genentech, Roche, hillsboro, manufacturing, oregon
Californian drugmaker Genentech is planning a $125 million expansion at its Hillsboro manufacturing centre in Oregon. The Roche subsidiary plant …
Immunocore appoints key scientist to board
March 31, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing immunocore, john bell
UK biotech Immunocore has appointed the Regius Professor of medicine at Oxford University and chairman of the office for the …
Addressing the adherence gap
March 30, 2015Research and Development, Sales and Marketing AstraZeneca, Kings College London, Professor John Weinman, adherence
Poor medication use in patients with long-term health conditions is widely recognised as a global problem that urgently needs to …
Novartis in major oncology drive
March 30, 2015Research and Development, Sales and Marketing Cancer, FDA, MHRA, Novartis, aduro, ceritinib, eams, early access, zykadia
Novartis says it is ‘stepping up its efforts’ in cancer by launching major initiatives to discover new treatments to combat …
J&J and Google partner to build surgical robots
March 30, 2015Medical Communications, Sales and Marketing Biogen, Ethicon, J&J, JJ, Johnson and Johnson, MS, google, robots
The medical device subsidiary of Johnson & Johnson Ethicon is to collaborate with Google to build surgical robots and perform …
GSK and UK government agree meningitis B vaccine deal
March 30, 2015Sales and Marketing AstraZeneca, Bexsero, GSK, Novartis, meningitis v, vaccines
The UK government has agreed a deal with GlaxoSmithKline to provide its meningitis B vaccine Bexsero on the NHS, after …
EMA committee recommends five drugs for approval
March 30, 2015Sales and Marketing Boehringer, CHMP, EMA, Eisai, Europe, Gardasil, Lenvima, Merck, akynzio, jardiance, lilly
Cancer and diabetes treatments are among those given the go ahead in the latest round of approvals by the EMA. …
Funding boost for UK drugs manufacturing
March 30, 2015Manufacturing and Production, Sales and Marketing ABPI, AstraZeneca, BIA, Bristol-Myers Squibb, Britest, Cambridge, Cambridge Crystallographic Data Centre, GlaxoSmithKline, Perceptive Engineering, Pfizer, Process Systems Enterprise, UCB, University of Leeds, amsci, mmip, stfc
The UK government is funding new manufacturing partnerships that will improve design processes and supply chain initiatives to lift the …
Bionor announces three new hires
March 30, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing barbara ruskin, bionor, kamilla rolsted, soren keller
Norwegian biotech Bionor has confirmed that three new members will be joining its executive management team. Dr Barbara Ruskin, senior …
BMS backs rheumatoid arthritis prevention trial
March 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis
Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
